LFST
Q4 2026 EPS Estimate
$0.03
Nov 5, 2026
Revenue Estimate
$431M
FY2026E EPS$0.16
FY2027E EPS$0.22

Analyst Sentiment

Wall St. Consensus
Buy
11 analysts·Moderate coverage
70
Score
9 Buy (82%)2 Hold (18%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
982%
Hold
218%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$9.00
-28.6%
Consensus
$13.00
+3.2%
Bull
$19.00
+50.8%
12-Month Target Range11 analysts
$9.00$13.00$19.00
Current $12.60Consensus
Current Price
$12.60
Upside to Consensus
$0.40

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+14.40%
EPS+36.68%
FY2028
Rev+14.87%
EPS+84.41%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028E
Revenue Avg$1.71B$1.95B$2.24B
Low$1.69B$1.93B$2.20B
High$1.72B$1.97B$2.32B
EBITDA Avg$152M$191M$284M
Low$146M$187M$244M
High$159M$196M$324M
EBIT Avg$87M$115M$194M
Low$80M$110M$154M
High$93M$119M$234M
Net Income Avg$61M$86M$158M
Low$55M$82M$122M
High$67M$90M$194M
EPS Avg$0.16$0.22$0.40
Low$0.14$0.21$0.31
High$0.17$0.23$0.50
Analysts (Rev / EPS)7 / 57 / 57 / 5
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$431M$438M$460M$492M$491M$502M$531M$571M
Low$431M$437M$455M$487M$485M$496M$525M$564M
High$432M$439M$465M$498M$496M$508M$537M$577M
EBITDA Avg$33M$35M$50M$53M$52M$58M$74M$82M
Low$28M$29M$49M$52M$51M$58M$73M$81M
High$38M$41M$50M$53M$52M$59M$75M$82M
EBIT Avg$18M$19M$33M$36M$34M$40M$55M$62M
Low$13M$14M$33M$35M$34M$40M$54M$61M
High$23M$25M$34M$36M$35M$41M$55M$63M
Net Income Avg$14M$15M$28M$30M$29M$34M$47M$54M
Low$10M$10M$28M$30M$28M$34M$47M$53M
High$19M$21M$28M$30M$29M$35M$48M$54M
EPS Avg$0.04$0.04$0.07$0.08$0.07$0.09$0.12$0.14
Low$0.02$0.03$0.07$0.08$0.07$0.09$0.12$0.14
High$0.05$0.05$0.07$0.08$0.08$0.09$0.12$0.14
Analysts (Rev / EPS)6 / 46 / 43 / 13 / 13 / 13 / 14 / 24 / 2

Earnings Surprises

Recent Analyst Actions

Aug 19, 2026BTIG
LifeStance price target raised to $19 from $16 at BTIG
Target:$19.00
+51.3%from $12.56
Aug 7, 2026Morgan Stanley
LifeStance price target raised to $13 from $10 at Morgan Stanley
Target:$13.00
+20.7%from $10.77
Aug 7, 2026BMO Capital
LifeStance price target raised to $13 from $10 at BMO Capital
Target:$13.00
+22.0%from $10.66
Aug 7, 2026BTIG
LifeStance price target raised to $16 from $15 at BTIG
Target:$16.00
+50.1%from $10.66
Jul 24, 2026BTIG
LifeStance price target raised to $15 from $12 at BTIG
Target:$15.00
+38.8%from $10.81
Jul 21, 2026Canaccord Genuity
LifeStance price target raised to $13 from $11 at Canaccord
Target:$13.00
+14.6%from $11.34
Jul 14, 2026Barclays
LifeStance price target raised to $13 from $9 at Barclays
Target:$13.00
+19.5%from $10.88
Jul 13, 2026KeyBanc
LifeStance price target raised to $13 from $11 at KeyBanc
Target:$13.00
+21.4%from $10.71
Jun 5, 2026Goldman Sachs
Goldman Sachs Starts Lifestance Health Group (LFST) at Neutral
Target:$9.00
+17.8%from $7.64
May 8, 2026Canaccord Genuity
LifeStance price target raised to $11 from $10 at Canaccord
Target:$11.00
+24.3%from $8.85
Feb 25, 2026BMO Capital
LifeStance price target raised to $10 from $8 at BMO Capital
Target:$10.00
+35.0%from $7.41
Feb 2, 2026BTIG
LifeStance price target raised to $11 from $10 at BTIG
Target:$11.00
+55.6%from $7.07
Jan 8, 2026KeyBanc
LifeStance price target raised to $8.50 from $6.50 at KeyBanc
Target:$8.50
+16.4%from $7.30
Jan 8, 2026Canaccord Genuity
LifeStance price target raised to $9 from $8 at Canaccord
Target:$9.00
+23.3%from $7.30
Dec 12, 2025BTIG
LifeStance price target raised to $10 from $9 at BTIG
Target:$10.00
+47.7%from $6.77
Dec 8, 2025Barclays
LifeStance initiated with an Overweight at Barclays
Target:$8.00
+24.8%from $6.41
May 27, 2025UBS
LifeStance upgraded to Buy from Neutral at UBS
Target:$8.50
+40.3%from $6.06
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.